# Lyme Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/lyme-disease

> 7 upcoming FDA catalysts in lyme Disease: VLA15 (PFE) on Dec 2026 to Mar 2027 (topline data readout); VLA15 (PFE) on December 2026 (primary completion); TNX-4800 (TNXP) on Q1 2027 (trial start); tp-05 (lotilaner) low dose (TARS) on October 2027 (primary completion); and 3 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 21, 2025 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05634811 (Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-21 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05634811)) |
| January 7, 2026 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05477524 (An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-07 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05477524)) |
| May 7, 2026 | [VLA15 topline data readout](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | completed | "NCT05634811 (Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-21 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-07." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05634811?tab=results)) |
| Dec 2026 to Mar 2027 | [VLA15 topline data readout](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | scheduled | "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07500506)) |
| December 2026 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | scheduled | "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07500506)) |
| Q1 2027 | [TNX-4800 trial start](https://sec-api.dev/pdufa/tnx-4800) | TNXP | Lyme disease | scheduled | "Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000149315226035741/ex99-01.htm)) |
| October 2027 | [Tp-05 (lotilaner) low dose primary completion](https://sec-api.dev/pdufa/tp-05-lotilaner) | TARS | Lyme Disease | scheduled | "NCT07562087 (A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07562087)) |
| Oct 2027 to Jan 2028 | [Tp-05 (lotilaner) low dose topline data readout](https://sec-api.dev/pdufa/tp-05-lotilaner) | TARS | Lyme Disease | scheduled | "NCT07562087 (A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07562087)) |
| Nov 2028 to Feb 2029 | [MRNA-1982 topline data readout](https://sec-api.dev/pdufa/mrna-1982) | MRNA | Lyme Disease | scheduled | "NCT07561294 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-09 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07561294)) |
| November 2028 | [MRNA-1982 primary completion](https://sec-api.dev/pdufa/mrna-1982) | MRNA | Lyme Disease | scheduled | "NCT07561294 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-09 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07561294)) |

## Drugs

- [VLA15](https://sec-api.dev/pdufa/vla15) (PFE)
- [TNX-4800](https://sec-api.dev/pdufa/tnx-4800) (TNXP)
- [Tp-05 (lotilaner) low dose](https://sec-api.dev/pdufa/tp-05-lotilaner) (TARS)
- [MRNA-1982](https://sec-api.dev/pdufa/mrna-1982) (MRNA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/lyme-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lyme Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/lyme-disease

```bibtex
@misc{secapidev_indications_lyme_disease_20261116,
  title        = {Lyme Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/lyme-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_lyme_disease_20261116","title":"Lyme Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/lyme-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
